



# An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

04/04/2025 23:40:00

## Main Information

**Primary registry identifying number**

LBCTR2022055038

**Protocol number**

CABL001A2001B

**MOH registration number**

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

**Primary sponsor**

Novartis Pharmaceuticals

**Primary sponsor: Country of origin**

Novartis Pharmaceuticals

**Date of registration in primary registry**

11/02/2025

**Date of registration in national regulatory agency**

**Public title**

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

**Acronym**

Asciminib Roll-over Study

**Scientific title**

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

**Acronym**

**Brief summary of the study: English**

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

**Brief summary of the study: Arabic**

دراسة تمديد لدى مرضى أنجزوا دراسة حول أسكيمينيب برعاية نوفارتيس وبحسب تقدير الباحث يستفيدون من مواصلة العلاج

**Health conditions/problem studied: Specify**

Chronic Myelogenous Leukemia  
Acute Lymphoblastic Leukemia

**Interventions: Specify**

- Drug: Asciminib single agent  
Taken orally, twice daily (BID) or once daily (QD), in fasting state





Other Name: ABL001

- Drug: Asciminib

Taken orally, once daily, in the morning with low-fat meal or twice daily in fasting state

Other Name: ABL001

- Drug: Imatinib

Taken orally, once daily, in the morning with low-fat meal

Other Name: STI571

- Drug: Nilotinib

Taken orally, twice daily, on an empty stomach

Other Name: AMN107

- Drug: Bosutinib

Taken orally, once daily, with food

- Drug: Dasatinib

Taken orally, once daily in a fasted state, 1 or 2 hours before a meal

Other Name: Sprycel

### Key inclusion and exclusion criteria: Inclusion criteria

1- Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment.

2- Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures.

### Key inclusion and exclusion criteria: Gender

Both

### Key inclusion and exclusion criteria: Specify gender

### Key inclusion and exclusion criteria: Age minimum

18

### Key inclusion and exclusion criteria: Age maximum

99

### Key inclusion and exclusion criteria: Exclusion criteria

1- Participant has been discontinued from parent study treatment.

2- Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.

3- Participant's ongoing treatment is currently approved and reimbursed at country level.

4- Pregnant or nursing (lactating) women.

5- Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.

6- Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information.

7- Applicable only for participants on bosutinib treatment that switch to asciminib treatment at enrollment:

- Asymptomatic pancreatitis

- abnormal ECG

- any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment

### Type of study

Interventional

### Type of intervention

Pharmaceutical

### Type of intervention: Specify type

N/A

### Trial scope

Safety

### Trial scope: Specify scope

N/A

### Study design: Allocation

Non-randomized controlled trial

### Study design: Masking

Open (masking not used)

### Study design: Control

Uncontrolled

### Study phase

4

### Study design: Purpose

Treatment

### Study design: Specify purpose

N/A

**Study design: Assignment**

Parallel

**Study design: Specify assignment**

N/A

**IMP has market authorization**

No

**IMP has market authorization: Specify****Name of IMP**

Asciminib

**Year of authorization****Month of authorization****Type of IMP**

Cell therapy

**Pharmaceutical class**

orally bioavailable specific BCR-ABL inhibitor with a novel mechanism of action

**Therapeutic indication**

Chronic Myelogenous Leukemia  
Acute Lymphoblastic Leukemia

**Therapeutic benefit**

increase OS & PFS

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration****Target follow-up duration: Unit****Number of groups/cohorts****Biospecimen retention**

None retained

**Biospecimen description**

N/A

**Target sample size**

1

**Actual enrollment target size**

1

**Date of first enrollment: Type**

Actual

**Date of first enrollment: Date**

11/10/2022

**Date of study closure: Type**

Actual

**Date of study closure: Date**

29/10/2027

**Recruitment status**

Complete

**Recruitment status: Specify****Date of completion**

11/10/2022

**IPD sharing statement plan**

Yes

**IPD sharing statement description**

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)

**Additional data URL**

<https://clinicaltrials.gov/ct2/show/record/NCT04877522?term=CABL001A2001B&draw=2&rank=1>

**Admin comments****Trial status**

Approved

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
clinicaltrials.gov	NCT04877522

## Sources of Monetary or Material Support

Name
Novartis Pharmaceuticals

## Secondary Sponsors

Name
N/A



## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Ali Bazarbachi	Beirut	Lebanon	+961 3 612434	bazarbac@aub.edu.lb	American University of Beirut Medical Center
Scientific	Hind Khairallah	Beirut	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l.

## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
American University of Beirut Medical Center	Ali Bazarbachi	Hematology Oncology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	03/05/2022	Fuad Ziyadeh	fz05@aub.edu.lb	+961 1 350000 ext:5445



## Countries of Recruitment

Name
Lebanon
Germany
Italy
Japan
Republic of Korea
Mexico
Portugal
Russian Federation
Spain
Turkey
United Kingdom
United States of America

## Health Conditions or Problems Studied

Condition	Code	Keyword
Chronic Myelogenous Leukemia	Leukaemia, unspecified (C95.9)	CML
Acute Lymphoblastic Leukemia	Leukaemia, unspecified (C95.9)	ALL

## Interventions

Intervention	Description	Keyword
Consenting, IMP administration	Consenting, IMP administration	Consenting, IMP administration

## Primary Outcomes

Name	Time Points	Measure
Number of participants with adverse events (AEs) and serious adverse events (SAEs)	5 years	All AEs and SAEs will be tabulated and listed for participants in the Safety Set by treatment group. From day of first administration of study treatment to 30 days after the last study treatment.



## Key Secondary Outcomes

Name	Time Points	Measure
Percentage of participants with clinical benefit as assessed by Investigator	5 years	Investigators' assessment of clinical benefit will be collected through the Investigator confirming that the patient is still benefiting from treatment. This will be evaluated and tabulated for participants in the Safety Set by treatment group at each visit.

## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files